

Philippe Devillier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/504420/publications.pdf>

Version: 2024-02-01

124
papers

5,345
citations

57758

44
h-index

98798

67
g-index

138
all docs

138
docs citations

138
times ranked

4852
citing authors

#	ARTICLE	IF	CITATIONS
1	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 70-80.e3.	2.9	272
2	Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 471-477.e1.	2.9	174
3	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	5.7	160
4	Impact of Allergic Rhinitis Symptoms on Quality of Life in Primary Care. <i>International Archives of Allergy and Immunology</i> , 2013, 160, 393-400.	2.1	159
5	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014, 44, 304-323.	6.7	154
6	Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study. <i>EBioMedicine</i> , 2021, 63, 103154.	6.1	143
7	Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care. <i>Clinical and Experimental Allergy</i> , 2013, 43, 881-888.	2.9	135
8	Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 165-177.	5.7	135
9	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. <i>Clinical and Translational Allergy</i> , 2016, 6, 47.	3.2	121
10	Pharmacological Characterization of Olodaterol, a Novel Inhaled β_2 -Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 53-62.	2.5	106
11	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. <i>Clinical and Translational Allergy</i> , 2018, 8, 45.	3.2	104
12	Peptides and histamine release from rat peritoneal mast cells. <i>European Journal of Pharmacology</i> , 1985, 117, 89-96.	3.5	103
13	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
14	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 135-143.e6.	2.9	101
15	Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1763-1774.	5.7	94
16	Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 857-865.	5.7	93
17	A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. <i>BMC Medicine</i> , 2014, 12, 71.	5.5	90
18	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87

#	ARTICLE	IF	CITATIONS
19	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1035-1042.	5.7	85
20	The expression and relaxant effect of bitter taste receptors in human bronchi. <i>Respiratory Research</i> , 2013, 14, 134.	3.6	82
21	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. <i>Clinical and Translational Allergy</i> , 2019, 9, 16.	3.2	81
22	Role of the N-terminal arginine in the histamine-releasing activity of substance P, bradykinin and related peptides. <i>European Journal of Pharmacology</i> , 1989, 168, 53-60.	3.5	80
23	The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 505-510.	5.7	77
24	Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. <i>Clinical and Experimental Allergy</i> , 2019, 49, 442-460.	2.9	73
25	The Role of Toll-Like Receptors in the Production of Cytokines by Human Lung Macrophages. <i>Journal of Innate Immunity</i> , 2020, 12, 63-73.	3.8	73
26	Update on the roles of distal airways in COPD. <i>European Respiratory Review</i> , 2011, 20, 007-22.	7.1	70
27	Work productivity in rhinitis using cell phones: The MASK pilot study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1475-1484.	5.7	69
28	Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1622-1631.	5.7	69
29	House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1181-1188.	5.7	68
30	How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 765-774.	5.7	67
31	Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction. <i>Respiratory Medicine</i> , 2013, 107, 1667-1674.	2.9	65
32	Clinical Pharmacokinetics and Pharmacodynamics of Desloratadine, Fexofenadine and Levocetirizine. <i>Clinical Pharmacokinetics</i> , 2008, 47, 217-230.	3.5	64
33	Update on the roles of distal airways in asthma. <i>European Respiratory Review</i> , 2009, 18, 80-95.	7.1	61
34	Roflumilast inhibits the release of chemokines and TNF- α from human lung macrophages stimulated with lipopolysaccharide. <i>British Journal of Pharmacology</i> , 2012, 165, 1877-1890.	5.4	61
35	Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 451-458.e5.	2.9	53
36	ARIA pharmacy 2018 – Allergic rhinitis care pathways for community pharmacy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1219-1236.	5.7	52

#	ARTICLE	IF	CITATIONS
37	The average Adjusted Symptom Score, a new primary efficacy endpoint for specific allergen immunotherapy trials. <i>Clinical and Experimental Allergy</i> , 2011, 41, 1282-1288.	2.9	51
38	Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 321-327.	5.7	51
39	Bitter Taste Receptors (TAS2Rs) in Human Lung Macrophages: Receptor Expression and Inhibitory Effects of TAS2R Agonists. <i>Frontiers in Physiology</i> , 2019, 10, 1267.	2.8	51
40	The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 163-169.	5.7	49
41	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016, 6, 29.	3.2	47
42	Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1317-1326.	5.7	47
43	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	5.7	46
44	15-Lipoxygenases regulate the production of chemokines in human lung macrophages. <i>British Journal of Pharmacology</i> , 2015, 172, 4319-4330.	5.4	45
45	Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB ₁ receptors. <i>British Journal of Pharmacology</i> , 2014, 171, 2767-2777.	5.4	42
46	Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 1331-1334.	5.7	38
47	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1041-1052.	5.7	38
48	The minimally important difference in the Rhinoconjunctivitis Total Symptom Score in grass-pollen-induced allergic rhinoconjunctivitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1689-1695.	5.7	35
49	Tiotropium reduction of lung inflammation in a model of chronic gastro-oesophageal reflux. <i>European Respiratory Journal</i> , 2010, 35, 1370-1376.	6.7	34
50	House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 249-257.	5.7	34
51	Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. <i>Clinical and Translational Allergy</i> , 2020, 10, 62.	3.2	34
52	How can we minimise the use of regular oral corticosteroids in asthma?. <i>European Respiratory Review</i> , 2020, 29, 190085.	7.1	34
53	The role of adenosine receptors in regulating production of tumour necrosis factor α and chemokines by human lung macrophages. <i>British Journal of Pharmacology</i> , 2010, 159, 1304-1311.	5.4	33
54	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. <i>World Allergy Organization Journal</i> , 2018, 11, 15.	3.5	33

#	ARTICLE	IF	CITATIONS
55	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK ^{air} App. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1672-1688.	5.7	32
56	Development and validation of combined symptom+medication scores for allergic rhinitis*. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2147-2162.	5.7	32
57	In allergic rhinitis, work, classroom and activity impairments are weakly related to other outcome measures. Clinical and Experimental Allergy, 2016, 46, 1456-1464.	2.9	31
58	Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 629-647.	5.7	31
59	Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK ^{air} . Clinical and Translational Allergy, 2021, 11, e12062.	3.2	31
60	Comparison of outcome measures in allergic rhinitis in children, adolescents and adults. Pediatric Allergy and Immunology, 2016, 27, 375-381.	2.6	30
61	Contrasting Effects of Adipokines on the Cytokine Production by Primary Human Bronchial Epithelial Cells: Inhibitory Effects of Adiponectin. Frontiers in Pharmacology, 2020, 11, 56.	3.5	25
62	Inhibition of the histamine-induced weal and flare response: a valid surrogate measure for antihistamine clinical efficacy?. Clinical and Experimental Allergy, 2007, 37, 400-414.	2.9	24
63	Clinical Relevance of Cluster Analysis in Phenotyping Allergic Rhinitis in a Real-Life Study. International Archives of Allergy and Immunology, 2015, 166, 231-240.	2.1	24
64	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clinical and Translational Allergy, 2016, 6, 41.	3.2	24
65	Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis. Expert Review of Clinical Immunology, 2017, 13, 1199-1206.	3.0	24
66	Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor- α and Chemokine Production by Human Lung Parenchyma. PLoS ONE, 2013, 8, e74640.	2.5	24
67	Desloratadine relieves nasal congestion and improves quality of life in persistent allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1663-1670.	5.7	23
68	Technical standards in allergen exposure chambers worldwide — an EAACI Task Force Report. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3589-3612.	5.7	23
69	CCR10+ ILC2s with ILC1-like properties exhibit a protective function in severe allergic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 933-943.	5.7	22
70	Expression and function of human hemokinin-1 in human and guinea pig airways. Respiratory Research, 2010, 11, 139.	3.6	20
71	Allergen immunotherapy: what is the added value of real-world evidence from retrospective claims database studies?. Expert Review of Respiratory Medicine, 2020, 14, 445-452.	2.5	20
72	Muscarinic receptors involved in airway vascular leakage induced by experimental gastro-oesophageal reflux. Life Sciences, 2008, 82, 949-955.	4.3	18

#	ARTICLE	IF	CITATIONS
73	Human lung and monocyte-derived macrophages differ with regard to the effects of β_2 -adrenoceptor agonists on cytokine release. <i>Respiratory Research</i> , 2017, 18, 126.	3.6	18
74	Metabolic reprogramming of LPS-stimulated human lung macrophages involves tryptophan metabolism and the aspartate-arginosuccinate shunt. <i>PLoS ONE</i> , 2020, 15, e0230813.	2.5	18
75	Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 46-53.	2.6	17
76	Google Trends and pollen concentrations in allergy and airway diseases in France. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1910-1919.	5.7	17
77	Adiponectin Inhibits the Production of TNF- α , IL-6 and Chemokines by Human Lung Macrophages. <i>Frontiers in Pharmacology</i> , 2021, 12, 718929.	3.5	17
78	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK- $\text{Air}^{\text{®}}$ real-world data. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2699-2711.	5.7	17
79	TNF- α -induced CXCL8 production by A549 cells: Involvement of the non-neuronal cholinergic system. <i>Pharmacological Research</i> , 2013, 68, 16-23.	7.1	16
80	The long-acting β_2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation. <i>British Journal of Pharmacology</i> , 2015, 172, 3537-3547.	5.4	15
81	Home spirometry in bronchiolitis obliterans after allogeneic haematopoietic cell transplant. <i>European Respiratory Journal</i> , 2018, 52, 1702328.	6.7	14
82	Effects of allergen immunotherapy in the MASK- Air study: a proof-of-concept analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3212-3214.	5.7	14
83	Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases. <i>Current Pharmaceutical Design</i> , 2017, 23, 2050-2059.	1.9	14
84	Biomedical detection dogs for the identification of SARS-CoV-2 infections from axillary sweat and breath samples ^{**} . <i>Journal of Breath Research</i> , 2022, 16, 037101.	3.0	14
85	Comparing the new antihistamines: the role of pharmacological parameters. <i>Clinical and Experimental Allergy</i> , 2006, 36, 5-7.	2.9	13
86	Expression and proliferative effect of hemokinin-1 in human B-cells. <i>Peptides</i> , 2011, 32, 1027-1034.	2.4	13
87	Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 108-114.	5.7	13
88	Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. <i>Current Medical Research and Opinion</i> , 2019, 35, 785-792.	1.9	13
89	300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1141-1151.	3.0	12
90	Tobacco-associated pulmonary vascular dysfunction in smokers: role of the ET-1 pathway. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2011, 300, L831-L839.	2.9	11

#	ARTICLE	IF	CITATIONS
91	Characterization of V0162, a new long-acting antagonist at human M3 muscarinic acetylcholine receptors. <i>Pharmacological Research</i> , 2015, 100, 117-126.	7.1	11
92	Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 759-770.e13.	2.9	11
93	Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β_2 -agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial. <i>Respiratory Medicine</i> , 2018, 141, 111-120.	2.9	11
94	Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 343-345.e2.	3.8	11
95	Is arginase a potential drug target in tobacco-induced pulmonary endothelial dysfunction?. <i>Respiratory Research</i> , 2015, 16, 46.	3.6	10
96	Determination of the minimally important difference in a nasal symptom score in house dust mite allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2191-2198.	5.7	10
97	Can β_2 -adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 118-134.	1.9	9
98	V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results. <i>Respiratory Research</i> , 2015, 16, 68.	3.6	9
99	Limited treatment adaptation despite poor asthma control in asthma patients treated with inhaled corticosteroids. <i>Journal of Asthma</i> , 2016, 53, 76-85.	1.7	9
100	Chloroquine Inhibits the Release of Inflammatory Cytokines by Human Lung Explants. <i>Clinical Infectious Diseases</i> , 2020, 71, 2265-2268.	5.8	9
101	Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model. <i>Clinical and Translational Allergy</i> , 2022, 12, e12128.	3.2	9
102	Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study. <i>International Journal of COPD</i> , 2019, Volume 14, 1839-1854.	2.3	8
103	Efficacy of immunoglobulin replacement therapy and azithromycin in severe asthma with antibody deficiency. <i>Allergology International</i> , 2020, 69, 215-222.	3.3	8
104	Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1033-1045.	2.9	8
105	Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3002-3014.	5.7	8
106	Characterisation of enkephalinase (EC 3.4.24.11) activity on various leukemic cells expressing the common acute lymphocytic leukemia antigen (CALLA). <i>FEBS Letters</i> , 1989, 248, 123-126.	2.8	7
107	Methodological aspects of a meta-analysis of grass pollen allergen sublingual immunotherapy tablets. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 314-315.e4.	2.9	7
108	Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells. <i>International Immunopharmacology</i> , 2016, 30, 1-8.	3.8	7

#	ARTICLE	IF	CITATIONS
109	Comparison of scores associating symptoms and rescue medication use for evaluating the efficacy of allergy immunotherapy in seasonal allergic rhinoconjunctivitis: results from five trials. <i>Clinical and Experimental Allergy</i> , 2017, 47, 254-263.	2.9	7
110	Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from <i>in vitro</i> allergen-release data. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 921-928.	3.0	7
111	Prostanoid Receptors Involved in Regulation of the Beating Rate of Neonatal Rat Cardiomyocytes. <i>PLoS ONE</i> , 2012, 7, e45273.	2.5	6
112	Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study. <i>BMJ Open</i> , 2020, 10, e035811.	1.9	5
113	Determining the minimal important differences in the RQLQ score with grass and tree allergy immunotherapy versus placebo in adults with moderate-to-severe allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1843-1851.	5.7	5
114	In smokers, Sonic hedgehog modulates pulmonary endothelial function through vascular endothelial growth factor. <i>Respiratory Research</i> , 2017, 18, 102.	3.6	4
115	Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist. <i>Frontiers in Pharmacology</i> , 2020, 11, 598702.	3.5	4
116	Clinical relevance of the relaxant effects of roflumilast on human bronchus: potentiation by a long-acting beta-2-agonist. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 725-731.	1.9	4
117	Rhinite allergique: Dymista®, une alternative thérapeutique. <i>Revue Française D'allergologie</i> , 2016, 56, 462-470.	0.2	1
118	Gamma globulin replacement therapy in uncontrolled, severe asthma associated with humoral immunodeficiency: A series of five case reports. <i>Journal of Asthma</i> , 2019, 56, 79-83.	1.7	1
119	Evaluating response to biologics in severe asthma: Precision or guess-timation?. <i>Respiratory Medicine and Research</i> , 2021, 80, 100813.	0.6	1
120	Letter to the editor. <i>Clinical Therapeutics</i> , 2007, 29, 2774-2775.	2.5	0
121	Response by P. Devillier, on behalf of the authors. <i>Clinical and Experimental Allergy</i> , 2012, 42, 806-806.	2.9	0
122	Allergic rhinitis treatment with sublingual immunotherapy. <i>Journal of Pediatrics</i> , 2015, 167, 1169-1172.	1.8	0
123	Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immuno Deficiency (CVID). , 2020, , .		0
124	Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021. <i>Respiratory Medicine and Research</i> , 2022, 81, 100889.	0.6	0